https://pioneerinstitute.org/wp-content/uploads/Untitled-design-2022-09-16T095137.929.png 512 1000 Gauri Binoy https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Gauri Binoy2022-09-16 09:49:442022-09-16 09:52:05Is this PBM tactic blocking healthcare access?
Utilization Management (UM) was originally a strategy designed to improve the safety, quality, and cost-effectiveness of physician prescribing. However, UM has grown exponentially over the last decade, becoming more a tactic for Pharmacy Benefit Managers (PBMs) to manage costs to benefit their bottom line.
https://pioneerinstitute.org/wp-content/uploads/Copy-of-11.-Employees-of-the-Public-Sector-5.png 512 1024 Gauri Binoy https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Gauri Binoy2022-08-08 15:26:072022-08-08 15:36:37The Realities Behind US Healthcare Spending
Healthcare policy is an all-encompassing term. It plays a role in every individual’s life; how it is curated, developed, and maintained has a significant long-term impact on the quality of life of any given community. It is critical that policymakers consistently adapt and amend healthcare policies in the ever-changing global pricing and affordability environment while providing funding support for optimal quality of care.
https://pioneerinstitute.org/wp-content/uploads/Copy-of-11.-Employees-of-the-Public-Sector-4.png 512 1024 William Smith https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png William Smith2022-08-08 10:31:192022-08-08 10:36:28Cures for Patients, Not Health Plan Profits, Make Drugs Valuable
To the astonishment of many observers, the Institute for Clinical and Economic Review (ICER) recently concluded that a $2.1 million gene therapy for a life-threatening blood disorder called beta thalassemia, is priced cost-effectively. The surprise was especially pleasant, given that ICER’s methodology had, in the past, displayed bias against rare disease treatments and undervalued the lives of people living with disabilities.